Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics Inc (AQST), Adaptimmune Therapeutics (ADAP)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics Inc (AQSTResearch Report) and Adaptimmune Therapeutics (ADAPResearch Report) with bullish sentiments.

Aquestive Therapeutics Inc (AQST)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aquestive Therapeutics Inc, with a price target of $34.00. The company’s shares closed last Monday at $3.22, close to its 52-week low of $2.95.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -15.3% and a 26.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics Inc with a $18.50 average price target.

See today’s analyst top recommended stocks >>

Adaptimmune Therapeutics (ADAP)

Cowen & Co. analyst Marc Frahm maintained a Buy rating on Adaptimmune Therapeutics today. The company’s shares closed last Monday at $1.55, close to its 52-week low of $1.37.

According to TipRanks.com, Frahm is ranked 0 out of 5 stars with an average return of -7.2% and a 37.3% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Magenta Therapeutics Inc, Applied Therapeutics Inc, and X4 Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.